Based on their findings, the authors estimate that one excess hospitalisation with hypomagnesaemia will occur among every 76,591 outpatients treated with a PPI for 90 days.
Prolonged use of PPIs has been associated with hypomagnesaemia. A Drug Safety Update article from the MHRA (see link below) advises healthcare professionals to consider measuring magnesium levels before starting PPI treatment and repeat measurements periodically during prolonged treatment, especially in those who will take a PPI concomitantly with digoxin or drugs that may cause hypomagnesaemia (e.g diuretics).